69 related articles for article (PubMed ID: 25295380)
1. [Gliomas and BRCA genes mutations: fortuitous association or imputability?].
Girardstein-Boccara L; Mari V; Met-Domestici M; Burel-Vandenbos F; Berthet P; Paquis P; Frenay MP; Lebrun-Frenay C
Bull Cancer; 2014 Sep; 101(9):795-802. PubMed ID: 25295380
[TBL] [Abstract][Full Text] [Related]
2. High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord.
Gessi M; Gielen GH; Dreschmann V; Waha A; Pietsch T
Acta Neuropathol; 2015 Sep; 130(3):435-7. PubMed ID: 26231952
[No Abstract] [Full Text] [Related]
3. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
[TBL] [Abstract][Full Text] [Related]
4. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
5. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
6. PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Rasheed BK; Stenzel TT; McLendon RE; Parsons R; Friedman AH; Friedman HS; Bigner DD; Bigner SH
Cancer Res; 1997 Oct; 57(19):4187-90. PubMed ID: 9331072
[TBL] [Abstract][Full Text] [Related]
7. Risk of endometrial carcinoma associated with BRCA mutation.
Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
9. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
Sloan EA; Cooney T; Oberheim Bush NA; Buerki R; Taylor J; Clarke JL; Torkildson J; Kline C; Reddy A; Mueller S; Banerjee A; Butowski N; Chang S; Mummaneni PV; Chou D; Tan L; Theodosopoulos P; McDermott M; Berger M; Raffel C; Gupta N; Sun PP; Li Y; Shah V; Cha S; Braunstein S; Raleigh DR; Samuel D; Scharnhorst D; Fata C; Guo H; Moes G; Kim JYH; Koschmann C; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Phillips JJ; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Nov; 138(5):877-881. PubMed ID: 31515627
[No Abstract] [Full Text] [Related]
10. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
11. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Jaworowska E; Tarnowska C; Lubiński J; Serrano-Fernández P; Huzarski T; Górski B; Masojć B; Jakubiszyn J; Korytowska A; Kram A; Rabczynski J; Lubiński J
Anticancer Res; 2009 Jul; 29(7):2703-5. PubMed ID: 19596949
[TBL] [Abstract][Full Text] [Related]
13. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.
Lima-Ramos V; Pacheco-Figueiredo L; Costa S; Pardal F; Silva A; Amorim J; Lopes JM; Reis RM
Cancer Genet Cytogenet; 2008 Jan; 180(1):14-9. PubMed ID: 18068527
[TBL] [Abstract][Full Text] [Related]
14. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
George SH; Milea A; Shaw PA
Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
[TBL] [Abstract][Full Text] [Related]
15. Counseling for male BRCA mutation carriers: a review.
Mohamad HB; Apffelstaedt JP
Breast; 2008 Oct; 17(5):441-50. PubMed ID: 18657973
[TBL] [Abstract][Full Text] [Related]
16. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
17. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.
Tea MK; Weghofer A; Wagner K; Singer CF
Maturitas; 2013 Jun; 75(2):148-51. PubMed ID: 23528734
[TBL] [Abstract][Full Text] [Related]
18. Missense mutation of the MET gene detected in human glioma.
Moon YW; Weil RJ; Pack SD; Park WS; Pak E; Pham T; Karkera JD; Kim HK; Vortmeyer AO; Fuller BG; Zhuang Z
Mod Pathol; 2000 Sep; 13(9):973-7. PubMed ID: 11007037
[TBL] [Abstract][Full Text] [Related]
19. Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer.
Elmariah SB; Huse J; Mason B; Leroux P; Lustig RA
Breast J; 2006; 12(5):470-4. PubMed ID: 16958968
[TBL] [Abstract][Full Text] [Related]
20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
